Loice Achieng Ombajo
Biographic Data
| ID | 9006751 |
|---|---|
| NAME | Loice Achieng Ombajo |
| GIVEN NAMES | Loice Achieng |
| FAMILY NAME | Ombajo |
| SIGNATURE | OMBAJO L A |
| AFFILIATIONS | University of Nairobi |
| ORCID | 0000-0003-4632-8792 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2025 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Bridging the gap between public health, academia and policy
The use of advanced analytics in public health policy remains hindered by a disconnect between researchers, policymakers and technical experts. Bridging this gap requires intentional knowledge translation strategies that facilitate interdisciplinary collaboration and real-world application of research findings. Hackathons, which bring together diverse stakeholders in a time-bound, solution-oriented format, offer an approach to address this challe…
Enhancing epidemic forecast usability for policymakers
The COVID-19 pandemic exposed critical gaps in the generation, interpretation, and use of epidemic forecasts for public health decision-making. We conducted a global mixed-methods study combining an online survey (n = 143, from 46 countries across all World Bank income groups) with 13 semi-structured interviews to examine how epidemic forecasts were perceived, used, and communicated by stakeholders involved in COVID-19 policy dialogues. Survey re…
Reserve antibiotics
New antibiotics active against multidrug resistant bacteria (MDR-B) are licensed by regulatory agencies based on pivotal trials that serve the primary purpose of obtaining marketing-authorization. There is increasing concern that they do not offer guidance on how to best use new antibiotics, in which population, and to what extent they overcome existing resistance. We reviewed the literature for pre-approval studies (phase 2 and 3 randomized cont…
No prominent works on this page.
Reserve antibiotics
New antibiotics active against multidrug resistant bacteria (MDR-B) are licensed by regulatory agencies based on pivotal trials that serve the primary purpose of obtaining marketing-authorization. There is increasing concern that they do not offer guidance on how to best use new antibiotics, in which population, and to what extent they overcome existing resistance. We reviewed the literature for pre-approval studies (phase 2 and 3 randomized cont…
Bridging the gap between public health, academia and policy
The use of advanced analytics in public health policy remains hindered by a disconnect between researchers, policymakers and technical experts. Bridging this gap requires intentional knowledge translation strategies that facilitate interdisciplinary collaboration and real-world application of research findings. Hackathons, which bring together diverse stakeholders in a time-bound, solution-oriented format, offer an approach to address this challe…
Enhancing epidemic forecast usability for policymakers
The COVID-19 pandemic exposed critical gaps in the generation, interpretation, and use of epidemic forecasts for public health decision-making. We conducted a global mixed-methods study combining an online survey (n = 143, from 46 countries across all World Bank income groups) with 13 semi-structured interviews to examine how epidemic forecasts were perceived, used, and communicated by stakeholders involved in COVID-19 policy dialogues. Survey re…
Business (2 works) · Medicine (2 works) · Public health (2 works) · Antibiotic Resistance in Bacteria (1 work) · Antibiotic Use and Resistance (1 work) · Antibiotics Pharmacokinetics and Efficacy (1 work) · Bioinformatics (1 work) · Biology (1 work) · Clinical trial (1 work) · Computer Science (1 work)